Trevi Therapeutics Stockholders Approve Key Amendments

Trevi Therapeutics ( (TRVI) ) just unveiled an announcement.

On June 11, 2025, Trevi Therapeutics, Inc. held its Annual Meeting of Stockholders, where stockholders approved an amendment to the 2019 Stock Incentive Plan to increase the shares available for issuance by 6,000,000 and elected Class III directors for terms expiring in 2028. The stockholders also ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for 2025, approved executive compensation, and recommended annual advisory votes on executive compensation.

The most recent analyst rating on (TRVI) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Trevi Therapeutics stock, see the TRVI Stock Forecast page.

Spark’s Take on TRVI Stock

According to Spark, TipRanks’ AI Analyst, TRVI is a Neutral.

Trevi Therapeutics shows promise with significant clinical progress and a strong cash position, essential for sustaining operations in a pre-revenue phase. However, ongoing financial losses and valuation risks temper the outlook. The stock’s technical indicators suggest strong momentum, but investors should be cautious due to potential volatility and financial risks inherent in early-stage biotechnology companies.

To see Spark’s full report on TRVI stock, click here.

More about Trevi Therapeutics

Average Trading Volume: 1,763,415

Technical Sentiment Signal: Buy

Current Market Cap: $754.8M

For a thorough assessment of TRVI stock, go to TipRanks’ Stock Analysis page.